[HTML][HTML] 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - ncbi.nlm.nih.gov
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association …
Writing Committee Members, SS Virani… - Journal of the American …, 2023 - jacc.org
Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …
N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice …
FLJ Visseren, F Mach, YM Smulders… - European heart …, 2021 - academic.oup.com
Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …
American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update
L Blonde, GE Umpierrez, SS Reddy, JB McGill… - Endocrine Practice, 2022 - Elsevier
Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …
evidence-based recommendations for the comprehensive care of persons with diabetes …
Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association
Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised …
Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
JR Ussher, DJ Drucker - Nature Reviews Cardiology, 2023 - nature.com
Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 …
Background We aimed to assess efficacy and safety, with a special focus on cardiovascular
safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine …
safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine …